Skip to Content

GSK, Xenoport Migraine Candidate Fails

From Associated Press (July 7, 2010)

NEW YORK -- A potential migraine headache treatment from GlaxoSmithKline and Xenoport Inc. failed to meet key treatment goals in a midstage study, the companies said Wednesday.

Shares of Xenoport Inc. plunged 27 percent, or $2.37, to $6.50 when the market opened.

The drug, labeled GSK1838262/XP13512, did not hit the target number of reduced migraine headache days experienced by patients and the companies cited an unexpectedly high response from patients taking a placebo.

The companies also reported the deaths of two patients. The first, due tobronchopneumonia, was deemed unrelated to the drug candidate test. The second involved an overdose of other medications and the relationship to the study drug could not be established.

The most common side effect was dizziness, though the company said eight patients taking the drug candidate experienced serious side effects. The study involved 526 patients.

Shares of GlaxoSmithKline, based in the U.K., fell 21 cents to $33.92.

Xenoport is based in Santa Clara, Calif.


Posted: July 2010